Maarit Anttila

Implementing treatment according to the guidelines is of paramount importance in locally advanced cervical cancer: a real-world study

Jaaskelainen, Ester; Karkkainen, Henna; Palmgren, Jan-Erik; Haataja, Marjut; Hinkula, Marianne; Anttila, Maarit, 2025, Frontiers in oncology, 15, 1562067. A1 Journal article (refereed), original research

Dynamic contrast-enhanced MRI to characterize angiogenesis in primary epithelial ovarian cancer: An exploratory study

Lindgren, Auni; Anttila, Maarit; Arponen, Otso; Hamalainen, Kirsi; Kononen, Mervi; Vanninen, Ritva; Sallinen, Hanna, 2023, European journal of radiology, 165, 110925. A1 Journal article (refereed), original research

Greater increases in intratumoral apparent diffusion coefficients after chemoradiotherapy predict better overall survival of patients with cervical cancer

Holopainen, Erikka; Lahtinen, Olli; Könönen, Mervi; Anttila, Maarit; Vanninen, Ritva; Lindgren, Auni, 2023, PLoS ONE, 18, 5, e0285786. A1 Journal article (refereed), original research

Neoadjuvant chemotherapy induces an elevation of tumour apparent diffusion coefficient values in patients with ovarian cancer

Reijonen, Milja; Holopainen, Erikka; Arponen, Otso; Könönen, Mervi; Vanninen, Ritva; Anttila, Maarit; Sallinen, Hanna; Rinta-Kiikka, Irina; Lindgren, Auni, 2023, Bmc cancer, 23, 299. A1 Journal article (refereed), original research

AAV8-mediated sVEGFR2 and sVEGFR3 gene therapy combined with chemotherapy reduces the growth and microvasculature of human ovarian cancer and prolongs the survival in mice

Kujala, Anni; Valkonen, Elina; Sallinen, Hanna; Tuppurainen, Laura; Laakso, Hanne; Ylä-Herttuala, Elias; Liimatainen, Timo; Kujala, Jouni; Jokelainen, Otto; Sironen, Reijo; Anttila, Maarit; Ylä-Herttuala, Seppo, 2022, Frontiers in medicine, 9, 1018208. A1 Journal article (refereed), original research

Patient functional recovery after a 23-h surgery — a prospective, follow-up study

Ruohoaho, Ulla-Maija; Aaltomaa, Sirpa; Kokki, Hannu; Anttila, Maarit; Kokki, Merja, 2022, Langenbecks archives of surgery, 407, 5, 2133-2142. A1 Journal article (refereed), original research

Postoperative pain in a prospectively assessed surgical short‐stay cohort: A subgroup analysis

Lappalainen, Emma; Ruohoaho, Ulla‐Maija; Kokki, Hannu; Aaltomaa, Sirpa; Anttila, Maarit; Gissler, Mika; Kokki, Merja, 2022, Acta anaesthesiologica scandinavica, 66, 10, 1193-1201. A1 Journal article (refereed), original research

Resilience, pain, and health-related quality of life in gynecological patients undergoing surgery for benign and malignant conditions: a 12-month follow-up study

Isokääntä, Siiri; Ruohoaho, Ulla Maija; Anttila, Maarit; Kokki, Hannu; Sintonen, Harri; Toroi, Petri; Kokki, Merja, 2022, Bmc womens health, 22, 1, 345. A1 Journal article (refereed), original research

Microvessels in Epithelial Ovarian Tumors: High Microvessel Density Is a Significant Feature of Malignant Ovarian Tumors

Sopo, Minna; Anttila, Maarit; Muukkonen, Oona-Tuuli; Ylä-Herttuala, Seppo; Kosma, Veli-Matti; Keski-Nisula, Leea; Sallinen, Hanna, 2020, Anticancer research, 40, 12, 6923-6931. A1 Journal article (refereed), original research

Dynamic contrast-enhanced perfusion parameters in ovarian cancer: Good accuracy in identifying high HIF-1α expression

Lindgren, A; Anttila, M; Rautiainen, S; Arponen, O; Hämäläinen, K; Könönen, M; Vanninen, R; Sallinen, H, 2019, PLoS ONE, 14, 8, e0221340. A1 Journal article (refereed), original research

Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer

Sopo, M; Anttila, M; Hämäläinen, K; Kivelä, A; Ylä-Herttuala, S; Kosma, VM; Keski-Nisula, L; Sallinen, H, 2019, Bmc cancer, 19, 584. A1 Journal article (refereed), original research

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

Mirza, Mansoor Raza; Lundqvist, Elisabeth Avail; Birrer, Michael; Christensen, Rene DePont; Nyvang, Gitte-Bettina; Malander, Susanne; Anttila, Maarit; Werner, Theresa L; Lund, Bente; Lindahl, Gabriel; Hietanen, Sakari; Peen, Ulla; Dimoula, Maria; Roed, Henrik; Knudsen, Anja Or; Staff, Synnove; Vistisen, Anders Krog; Bjorge, Line; Mäenpää, Johanna U, 2019, The Lancet Oncology, 20, 10, 1409-1419. A1 Journal article (refereed), original research

Prognostic Value of Preoperative Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Epithelial Ovarian Cancer

Lindgren, Auni; Anttila, Maarit; Arponen, Otso; Rautiainen, Suvi; Könönen, Mervi; Vanninen, Ritva; Sallinen, Hanna, 2019, European journal of radiology, 115, 66-73. A1 Journal article (refereed), original research

Primary and metastatic ovarian cancer: Characterization by 3.0T diffusion-weighted MRI

Lindgren A, Anttila M, Rautiainen S, Arponen O, Kivelä A, Mäkinen P, Härmä K, Hämäläinen K, Kosma V-M, Ylä-Herttuala S, Vanninen R, Sallinen H, 2017, European radiology, 27, 9, 4002-4012. A1 Journal article (refereed), original research

Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer

Sallinen H, Heikura T, Koponen J, Kosma VM, Heinonen S, Ylä-Herttuala S, Anttila M, 2014, Bmc cancer, 14, 1, 1-10. A1 Journal article (refereed), original research

Preclinical Safety, Toxicology, and Biodistribution Study of Adenoviral Gene Therapy with sVEGFR-2 and sVEGFR-3 Combined with Chemotherapy for Ovarian Cancer

Tuppurainen L, Sallinen H, Kokki E, Koponen J, Anttila M, Pulkkinen K, Heikura T, Toivanen P, Hämäläinen K, Kosma VM, Heinonen S, Alitalo K, Ylä-Herttuala S, 2013, Human gene therapy. clinical development, 24, 1, 29-37. A1 Journal article (refereed), original research

Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma

Sopo M, Anttila M, Sallinen H, Tuppurainen L, Laurema A, Laidinen S, Hamalainen K, Tuunanen P, Koponen JK, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S, 2012, International journal of cancer, 131, 10, 234-2401. A1 Journal article (refereed), original research

Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.

Vuorela M, Pylkäs K, Hartikainen JM, Sundfeldt K, Lindblom A, von Wachenfeldt Wäppling A, Haanpää M, Puistola U, Rosengren A, Anttila M, Kosma VM, Mannermaa A, Winqvist R., 2011, Breast cancer research and treatment, 130, 3, 1003-10. A1 Journal article (refereed), original research

Hyaluronan in human malignancies

Sironen RK, Tammi M, Tammi R, Auvinen PK, Anttila M & Kosma VM, 2011, Experimental cell research, 317, 4, 383-391. A1 Journal article (refereed), original research

Munasarjakystat - tarvitseeko aina leikata tai edes seurata?

Kuivasaari-Pirinen P, Anttila M, 2011, Duodecim, 127, 1857-1863. A1 Journal article (refereed), original research

VEGFR-1 and -3 and angiopoietin receptor Tie2 targeted gene therapy prevents the growth of solid human ovarian cancer in mice compared to cotargeting Tie1 and Tie2

Sallinen H, Anttila M, Gröhn O, Koponen J, Hämäläinen K, Kholova I, Heikura T, Kosma VM, Heinonen S, Alitalo K, Ylä-Herttuala S, 2011, Cancer gene therapy, 18, 2, 100-9. A1 Journal article (refereed), original research

Antiangiogenic gene therapy with soluble VEGFR-1, -2 and -3 reduces the growth of solid human ovarian carcinoma in mice

Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma V-M, Heinonen S, Alitalo K, Yla-Herttuala S, 2009, Molecular therapy, 17, 2, 278-284. A1 Journal article (refereed), original research

Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYALI and hyaluronan content

Nykopp TK, Rilla K, Sironen R, Tammi MI, Tammi RH, Hämäläinen K, Heikkinen A-M, Komulainen M, Kosma V-M, Anttila M, 2009, Bmc cancer, 9, 143, [9 p.]. A1 Journal article (refereed), original research

Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression

Tuhkanen H, Soini Y, Kosma V-M, Anttila M, Sironen R, Hämäläinen K, Kukkonen L, Virtanen I, Mannermaa A, 2009, Bmc cancer, 9, 289. A1 Journal article (refereed), original research

Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer

Sillanpää S, Anttila M, Suhonen K, Hämäläinen K, Turpeenniemi-Hujanen T, Puistola U, Tammi M, Sironen R, Saarikoski S, Kosma VM, 2007, Tumor biology, 28, 5, 280-289. A1 Journal article (refereed), original research

Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer

Sillanpää S, Anttila M, Voutilainen K, Ropponen K, Turpeenniemi-Hujanen T, Puistola U, Tammi R, Tammi M, Sironen R, Saarikoski S, Kosma V-M, 2007, Gynecologic oncology, 104, 296-303. A1 Journal article (refereed), original research

A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up

Sallinen H, Anttila M, Narvainen J, Ordén M-R, Ropponen K, Kosma V-M, Heinonen S, Yla-Herttuala S, 2006, Gynecologic oncology, 103, 1, 315-320. A1 Journal article (refereed), original research

Frequent gene dosage alterations in stromal cells of epithelial ovarian carcinomas

Tuhkanen H, Anttila M, Kosma V-M, Heinonen S, Juhola M, Helisalmi S, Kataja V, Mannermaa A, Helisalmi S, 2006, International journal of cancer, 119, 1345-1353. A1 Journal article (refereed), original research

Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer

Voutilainen KA, Anttila MA, Sillanpää SM, Ropponen KM, Saarikoski SV, Juhola MT, Kosma V-M, 2006, Journal of clinical pathology, 59, 460-467. A1 Journal article (refereed), original research

Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression

Sillanpää SM, Anttila MA, Voutilainen KA, Ropponen KM, Sironen RK, Saarikoski SV, Kosma V-M, 2006, International journal of cancer, 119, 1792-1799. A1 Journal article (refereed), original research

Effect of endometriosis on IVF/ICSI outcome: stage III/IV endometriosis worsens cumulative pregnancy and live-born rates

Kuivasaari P, Hippeläinen M, Anttila M, Heinonen S, 2005, Human reproduction, 20, 11, 3130-3135. A1 Journal article (refereed), original research

Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p

Tuhkanen H, Anttila M, Kosma V-M, Ylä-Herttuala S, Heinonen S, Kuronen A, Juhola M, Tammi R, Tammi M, Mannermaa A, 2004, International journal of cancer, 109, 2, 247-252. A1 Journal article (refereed), original research

Marked allelic imbalance on chromosome 5q31 does not explain a-catenin expression in epithelial ovarian cancer

Tuhkanen H, Anttila M, Kosma V-M, Puolakka J, Juhola M, Heinonen S, Mannermaa A, 2004, Gynecologic oncology, 94, 416-421. A1 Journal article (refereed), original research

Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis

Voutilainen K, Anttila M, Sillanpää S, Tammi R, Tammi M, Saarikoski S, Kosma V-M, 2003, International journal of cancer, 107, 359-364. A1 Journal article (refereed), original research

Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors

Hiltunen ELJ, Anttila M, Kultti A, Ropponen K, Penttinen J, Yliskoski M, Kuronen AT, Juhola M, Tammi R, Tammi M, Kosma V-M, 2002, Cancer research, 62, 6410-6413. D1 Article in a trade journal

Reproductive risk factors, doppler findings, and outcome of affected births in placental abruption: a population-based analysis

Toivonen S, Heinonen S, Anttila M, Kosma V-M, Saarikoski S, 2002, American journal of perinatology, 19, 8, 451-459. A1 Journal article (refereed), original research

Biological Predictors of Disease Progression and Patient Survival in Epithelial Ovarian Cancer

Anttila M, 2000, Kuopio University Publications D. Medical Sciences. G5 Doctoral dissertation (article)

Expression of transcription factor AP-2 alfa predicts survival in epithelial ovarian cancer

Anttila MA, Kellokoski JK, Moisio KI, Mitchell PJ, Saarikoski S, Syrjänen K, Kosma V-M, 2000, British journal of cancer, 82, 12, 1974-1983. A1 Journal article (refereed), original research

Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables

Launonen V, Mannermaa A, Stenbäck F, Kosma V-M, Puistola U, Huusko P, Anttila M, Bloigu R, Saarikoski S, Kauppila A, Winqvist R, 2000, Cancer genetics and cytogenetics, 122, 49-54. A1 Journal article (refereed), original research

Failure to demonstrate human papillomavirus DNA in epithelial ovarian cancer by general primer PCR

Anttila M, Syrjänen S, Ji H, Saarikoski S, Syrjänen K, 1999, Gynecologic oncology, 72, 337-341. A1 Journal article (refereed), original research

The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer

Anttila MA, Ji H, Juhola MT, Saarikoski SV, Syrjänen KJ, 1999, International journal of gynecological pathology, 18, 1, 42-51. A1 Journal article (refereed), original research

p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer

Anttila MA, Kosma V-M, Hongxiu J, Puolakka J, Juhola M, Saarikoski S, Syrjänen K, 1999, British journal of cancer, 79, 11/12, 1870-1878. A1 Journal article (refereed), original research

Clinical significance of alfa-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer

Anttila M, Kosma V-M, Ji H, Wei-Ling X, Puolakka J, Juhola M, Saarikoski S, Syrjänen K, 1998, Journal of clinical oncology, 16, 8, 2591-2600. A1 Journal article (refereed), original research

Refine your search

Implementing treatment according to the guidelines is of paramount importance in locally advanced cervical cancer: a real-world study

Dynamic contrast-enhanced MRI to characterize angiogenesis in primary epithelial ovarian cancer: An exploratory study

Greater increases in intratumoral apparent diffusion coefficients after chemoradiotherapy predict better overall survival of patients with cervical cancer

Neoadjuvant chemotherapy induces an elevation of tumour apparent diffusion coefficient values in patients with ovarian cancer

AAV8-mediated sVEGFR2 and sVEGFR3 gene therapy combined with chemotherapy reduces the growth and microvasculature of human ovarian cancer and prolongs the survival in mice

Patient functional recovery after a 23-h surgery — a prospective, follow-up study

Postoperative pain in a prospectively assessed surgical short‐stay cohort: A subgroup analysis

Resilience, pain, and health-related quality of life in gynecological patients undergoing surgery for benign and malignant conditions: a 12-month follow-up study

Microvessels in Epithelial Ovarian Tumors: High Microvessel Density Is a Significant Feature of Malignant Ovarian Tumors

Dynamic contrast-enhanced perfusion parameters in ovarian cancer: Good accuracy in identifying high HIF-1α expression

Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

Prognostic Value of Preoperative Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Epithelial Ovarian Cancer

Primary and metastatic ovarian cancer: Characterization by 3.0T diffusion-weighted MRI

Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer

Preclinical Safety, Toxicology, and Biodistribution Study of Adenoviral Gene Therapy with sVEGFR-2 and sVEGFR-3 Combined with Chemotherapy for Ovarian Cancer

Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma

Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.

Hyaluronan in human malignancies

Munasarjakystat - tarvitseeko aina leikata tai edes seurata?

VEGFR-1 and -3 and angiopoietin receptor Tie2 targeted gene therapy prevents the growth of solid human ovarian cancer in mice compared to cotargeting Tie1 and Tie2

Antiangiogenic gene therapy with soluble VEGFR-1, -2 and -3 reduces the growth of solid human ovarian carcinoma in mice

Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYALI and hyaluronan content

Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression

Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer

Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer

A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up

Frequent gene dosage alterations in stromal cells of epithelial ovarian carcinomas

Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer

Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression

Effect of endometriosis on IVF/ICSI outcome: stage III/IV endometriosis worsens cumulative pregnancy and live-born rates

Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p

Marked allelic imbalance on chromosome 5q31 does not explain a-catenin expression in epithelial ovarian cancer

Obstetric prognosis after placental abruption

CD44 expression indicates favorable prognosis in epithelial ovarian cancer

Obstetric outcome in women with endometriosis-a matched case-control study

Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis

Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors

Reproductive risk factors, doppler findings, and outcome of affected births in placental abruption: a population-based analysis

Biological Predictors of Disease Progression and Patient Survival in Epithelial Ovarian Cancer

Expression of transcription factor AP-2 alfa predicts survival in epithelial ovarian cancer

Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables

Failure to demonstrate human papillomavirus DNA in epithelial ovarian cancer by general primer PCR

The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer

p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer

Clinical significance of alfa-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer